US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Decoy Therapeutics Inc

1.25

+0.435053.37%

Post-market: 1.03-0.2200-17.60%19:59 EST

Volume:108.81M

Turnover:142.50M

Market Cap:7.98M

PE:-0.03

High:1.41

Open:1.35

Low:1.07

Close:0.8150

52wk High:108.00

52wk Low:0.5148

Shares:6.38M

Float Shares:6.34M

Volume Ratio:72.71

T/O Rate:1715.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-39.1909

EPS(LYR):-86.9214

ROE:-139.55%

ROA:-69.91%

PB:1.88

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Decoy Therapeutics Inc

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

2

Office Location:

One Broadway,14th Floor,Cambridge,Massachusetts,United States

Website:

http://www.salariuspharma.com

Zip Code:

02142

Phone:

- -

Fax:

- -

Introduction:

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Directors

Name

Position

Frederick E. Pierce

Director and Chief Executive Officer

William K. McVicar

Chair

Arnold C. Hanish

Director

David J. Arthur

Director

Jonathan Lieber

Director

Paul Lammers

Director

Tess Burleson

Director

Shareholders

Name

Position

Frederick E. Pierce

Director and Chief Executive Officer

Mark J. Rosenblum

Executive Vice President of Finance and Chief Financial Officer

Barbara Hibner

Chief Scientific Officer

Peter Marschel

Chief Business Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DCOY/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":1.25,"timestamp":1768338000000,"preClose":0.815,"halted":0,"volume":108810866,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.25,"latestTime":"19:59 EST","volume":1719614,"amount":1907282.5938,"timestamp":1768352390180},"delay":0,"floatShares":6341106,"shares":6384200,"eps":-39.1909,"marketStatus":"Not Yet Opened","change":0.435,"latestTime":"01-13 16:00:00 EST","open":1.35,"high":1.41,"low":1.07,"amount":142501212.763518,"amplitude":0.417178,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-39.1909,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":0,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":0.815,"preHourTrading":{"tag":"盘前","latestPrice":1.3597,"preClose":0.815,"latestTime":"09:29 EST","volume":24520606,"amount":34173289.675536,"timestamp":1768314598862},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.25,"latestTime":"19:59 EST","volume":1719614,"amount":1907282.5938,"timestamp":1768352390180},"volumeRatio":72.708437},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":6341106,"roa":"-69.91%","roe":"-139.55%","lyrEps":-86.921415,"volumeRatio":72.708437,"shares":6384200,"dividePrice":0,"high":1.41,"amplitude":0.417178,"preClose":0.815,"low":1.07,"week52Low":0.5148,"pbRate":"1.88","week52High":108,"institutionHeld":0,"latestPrice":1.25,"eps":-39.1909,"divideRate":0,"volume":108810866,"delay":0,"ttmEps":-39.1909,"open":1.35,"prevYearClose":0.6488,"prevWeekClose":0.8198,"prevMonthClose":0.6488,"prevQuarterClose":0.6488,"fiveDayClose":0.65,"twentyDayClose":0.78,"sixtyDayClose":4.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-01-12","current":-0.031895,"percent":0.5,"low":-1.071522,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"high":-0.982229,"avg":-1.033168,"sd":0.037524,"marketCap":5233748},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-12","current":-1.045754,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"marketCap":5233748}],"updateTime":1768377346982},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":330031056,"employeeNum":2,"address":"One Broadway,14th Floor,Cambridge,Massachusetts,United States","zipCode":"02142"},"stockCompanyDetail":{"websiteUrl":"http://www.salariuspharma.com","stockEarnings":[{"period":"1week","weight":0.9231},{"period":"1month","weight":0.6026},{"period":"3month","weight":-0.7283},{"period":"6month","weight":-0.8641},{"period":"1year","weight":-0.9773},{"period":"ytd","weight":0.9266}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.099389},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.047904},{"month":3,"riseRate":0.454545,"avgChangeRate":0.000826},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.073659},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.005048},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.047064},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.136217},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.111993},{"month":9,"riseRate":0.090909,"avgChangeRate":-0.12638},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.128321},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062226},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.07199}],"exchange":"NASDAQ","name":"Decoy Therapeutics Inc","nameEN":"Decoy Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":{"directors":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"William K. McVicar","position":"Chair"},{"name":"Arnold C. Hanish","position":"Director"},{"name":"David J. Arthur","position":"Director"},{"name":"Jonathan Lieber","position":"Director"},{"name":"Paul Lammers","position":"Director"},{"name":"Tess Burleson","position":"Director"}],"executives":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"Mark J. Rosenblum","position":"Executive Vice President of Finance and Chief Financial Officer"},{"name":"Barbara Hibner","position":"Chief Scientific Officer"},{"name":"Peter Marschel","position":"Chief Business Officer"}]}}}